Insulin Detemir vs Insulin Degludec — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Insulin Analog

Insulin Detemir

Brand: LEVEMIR

First FDA approval: 2006-03-27

Insulin Analog

Insulin Degludec

Brand: TRESIBA

First FDA approval: 2015-09-25

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$9.02Per unit

Average NADACAcross all dosage forms and strengths

—

$13.60Up to $22.72

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$155.5MFull year

$2.69BFull year

Part D claims (CY24)Total fills, all strengths

725K275K beneficiaries

3.5M1.2M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$215Per claim, all NDCs

$777Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

3Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

DiscontinuedSee drug profile

Generic availableFDA Orange Book

NoBrand-only